Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADC 5311
- Development stage
- Preclinical
- Lead developer
- Adienne S.r.l. S.U.
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ADC 5311 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Adienne S.r.l. S.U. for the treatment of malignant mesothelioma. The drug consists of begelomab, an anti-CD26 monoclonal antibody, conjugated to a cytotoxic payload. Its mechanism of action involves the targeted delivery of the cytotoxic agent to tumor cells expressing CD26 (also known as dipeptidyl peptidase 4), a cell surface protein that is highly expressed in malignant mesothelioma. Upon binding to CD26, the ADC is internalized, releasing the toxin to induce cell death specifically in tumor cells while sparing healthy tissue. This targeted approach is designed to enhance therapeutic efficacy and reduce systemic toxicity for patients with mesothelioma.
- Other names
- Begelomab-based ADC
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on ADC 5311.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADC 5311.